Ethan B. Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in cholangiocarcinoma.
Poll|Poll|June 16, 2016
Abdominal Mass Found in 43-Year-Old Patient
Author(s)Cesar A. Moran, MD
A 43-year-old woman presents with abdominal pain. A mass is found in her right side, and a biopsy is performed. What is your diagnosis?
Advertisement
A 43-year-old woman presents with abdominal pain. A mass is found in her right side, and a biopsy is performed.
Based on the image shown, what is your diagnosis?
Advertisement
Related to this article
In the phase 3 CERVINO trial, etentamig showed an early overall survival signal in patients with triple-class exposed relapsed/refractory multiple myeloma.
In the phase 2 IBEX trial, iberdomide plus subcutaneous daratumumab post-transplant maintenance improved MRD status in patients with multiple myeloma.
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Acting on a HER2 Result and Navigating Access to Therapy
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
5